Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield
Connecticut
06877
U.S.A.
Phone:
203-798-9988
Fax:
n/a
|
About Boehringer Ingelheim
The Boehringer Ingelheim group of companies is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the privately–owned company currently has approximately 41,300 employees and 135 affiliated companies spread around the globe.
Boehringer Ingelheim is research-driven and dedicated to the discovery, development, manufacture and marketing of innovative human and animal health care products.
In 2008, Boehringer Ingelheim posted net sales of U.S. $17.0 billion (11.6 billion euro) while spending nearly one fifth of net sales on research and development in its largest business segment, Prescription Medicines.
Boehringer Ingelheim Corporation, based in Ridgefield, CT, is the U.S. headquarters to seven subsidiaries, and a member of the Boehringer Ingelheim worldwide group of companies. The U.S. Boehringer Ingelheim subsidiaries employ nearly 9,000 people.
Value Through Innovation
Our vision of Value through Innovation (VTI) guides our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. It also helps us foster value creation throughout our company and to look to the future with constantly renewed commitment and ambition.
Our Lead & Learn principles outline ways in which we can build on our culture of working together to realize and deliver Value through Innovation. These principles encourage us to take risks, ask questions, and seize opportunities in an environment of shared leadership and learning.
Boehringer Ingelheim in the United States
Boehringer Ingelheim, Ltd. was established in the U.S. in 1971 to market respiratory and cardiovascular medications. Boehringer Ingelheim Corporation was later established in 1986 to serve as the parent organization in the U.S. for the original pharmaceutical company and its subsequent acquisitions.
Pharmaceutical operations expanded in North America with the acquisition of Roxane Laboratories, Inc. in Columbus, Ohio in 1978, a company with expertise in cancer and palliative care.
Boehringer Ingelheim went on to achieve a major advance into the hospital market in late 1997 through the acquisition of Ben Venue Laboratories, Inc., a manufacturer and marketer of sterile injectable pharmaceuticals.
In 1999, Boehringer Ingelheim Consumer Health Care Products was established to market over-the-counter health care products.
In the animal health arena, Boehringer Ingelheim Corporation purchased the Anchor Serum Company in 1981, which became the foundation of what is today Boehringer Ingelheim Vetmedica, Inc. Boehringer Ingelheim Corporation made further inroads into the animal health business with the acquisition of Fermenta Animal Health in 1995 and the swine health company NOBL Laboratories in early 1997.
Boehringer Ingelheim Corporation first established its Fine Chemicals operations in the U.S. in the early 1970s. Today, Boehringer Ingelheim Chemicals, Inc. in Petersburg, VA is the core of Boehringer Ingelheim’s Fine Chemicals business unit in the United States.
Boehringer Ingelheim was founded in Ingelheim am Rhein (Germany) in 1885, where the corporate headquarters are located today. To learn more about our history, please visit our global website.
Email:
Ownership:
Web Site:
Boehringer Ingelheim Pharmaceuticals, Inc.
Employees:
More than 9,000 employees in the US; 41,300+ worldwide
Symbol:
|
|
|